Vanmechelen E - Search Results

1

Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.

Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, Karikari TK, Simrén J, Vanmechelen E, Armstrong NJ, Hone E, Asih PR, Taddei K, Doré V, Villemagne VL, Sohrabi HR, Zetterberg H, Masters CL, Blennow K, Martins RN. Chatterjee P, et al. Among authors: vanmechelen e. Alzheimers Dement. 2022 Jun;18(6):1141-1154. doi: 10.1002/alz.12447. Epub 2021 Sep 8. Alzheimers Dement. 2022. PMID: 34494715

2

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: vanmechelen e. Dement Geriatr Cogn Disord. 2002;13(2):112-8. doi: 10.1159/000048642. Dement Geriatr Cogn Disord. 2002. PMID: 11844893

3

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Andreasen N, et al. Among authors: vanmechelen e. Acta Neurol Scand Suppl. 2003;179:47-51. doi: 10.1034/j.1600-0404.107.s179.9.x. Acta Neurol Scand Suppl. 2003. PMID: 12603251 Clinical Trial.

4

Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets.

Olsson A, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Olsson A, et al. Among authors: vanmechelen e. Dement Geriatr Cogn Disord. 2003;16(2):93-7. doi: 10.1159/000070681. Dement Geriatr Cogn Disord. 2003. PMID: 12784033

5

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.

Blennow K, Vanmechelen E. Blennow K, et al. Among authors: vanmechelen e. Brain Res Bull. 2003 Aug 15;61(3):235-42. doi: 10.1016/s0361-9230(03)00086-8. Brain Res Bull. 2003. PMID: 12909293 Review.

6

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K. Hampel H, et al. Among authors: vanmechelen e. Arch Gen Psychiatry. 2004 Jan;61(1):95-102. doi: 10.1001/archpsyc.61.1.95. Arch Gen Psychiatry. 2004. PMID: 14706948

7

Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.

Höglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Höglund K, et al. Among authors: vanmechelen e. Arch Neurol. 2004 Mar;61(3):333-7. doi: 10.1001/archneur.61.3.333. Arch Neurol. 2004. PMID: 15023808 Clinical Trial.

8

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K. Olsson A, et al. Among authors: vanmechelen e. Clin Chem. 2005 Feb;51(2):336-45. doi: 10.1373/clinchem.2004.039347. Epub 2004 Nov 24. Clin Chem. 2005. PMID: 15563479 Clinical Trial.

9

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E. Vanderstichele H, et al. Among authors: vanmechelen e. Clin Chem. 2005 Sep;51(9):1650-60. doi: 10.1373/clinchem.2005.051201. Epub 2005 Jul 14. Clin Chem. 2005. PMID: 16020497

10

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I. Iqbal K, et al. Among authors: vanmechelen e. Ann Neurol. 2005 Nov;58(5):748-57. doi: 10.1002/ana.20639. Ann Neurol. 2005. PMID: 16247771

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page